Related Experiment Video
Updated: Dec 18, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer
Dominika Bębnowska1, Ewelina Grywalska2, Paulina Niedźwiedzka-Rystwej1
1Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.
Abstract:
Gastric cancer (GC) is one of the most commonly diagnosed malignancies and, unfortunately, still has a high mortality rate. Recent research points to CAR-T immunotherapy as a promising treatment for this disease. Using genetically engineered T cells designed to target a previously selected antigen, researchers are able to harness the natural anti-tumor activity of T cells. For therapy to be successful, however, it is essential to choose antigens that are present on tumor cells but not on healthy cells. In this review, we present an overview of the most important targets for CAR-T therapy in the context of GC, including their biologic function and therapeutic application. A number of clinical studies point to the following as important markers in GC: human epidermal growth factor receptor 2, carcinoembryonic antigen, mucin 1, epithelial cell adhesion molecule, claudin 18.2, mesothelin, natural-killer receptor group 2 member D, and folate receptor 1. Although these markers have been met with some success, the search for new and improved targets continues. Key among these novel biomarkers are the B7H6 ligand, actin-related protein 2/3 (ARP 2/3), neuropilin-1 (NRP-1), desmocollin 2 (DSC2), anion exchanger 1 (AF1), and cancer-related antigens CA-72-4 and CA-19-9.
Insights
CAR-T immunotherapy shows promise for gastric cancer (GC). Researchers are identifying specific antigens on tumor cells to effectively target cancer while sparing healthy cells, advancing treatment options.
Area of Science:
- Oncology
- Immunotherapy
- Biotechnology
Background:
- Gastric cancer (GC) remains a leading cause of cancer mortality worldwide.
- Chimeric Antigen Receptor T (CAR-T) cell therapy offers a promising new avenue for treating GC.
- Successful CAR-T therapy relies on identifying tumor-specific antigens for targeted cell recognition.
Purpose of the Study:
- To review current and novel antigen targets for CAR-T therapy in gastric cancer.
- To discuss the biological function and therapeutic relevance of these targets.
- To highlight ongoing research for improved CAR-T targets in GC.
Main Methods:
- Review of existing scientific literature on CAR-T therapy targets in gastric cancer.
- Analysis of biological functions and clinical study outcomes for identified antigens.
- Identification and categorization of established and novel biomarkers.
Main Results:
- Several established antigens like human epidermal growth factor receptor 2 (HER2) and carcinoembryonic antigen (CEA) have shown potential in GC CAR-T therapy.
- Emerging novel biomarkers include B7H6 ligand, actin-related protein 2/3 (ARP 2/3), neuropilin-1 (NRP-1), desmocollin 2 (DSC2), anion exchanger 1 (AF1), and cancer antigens CA-72-4 and CA-19-9.
- The ongoing search for optimal targets aims to enhance efficacy and reduce off-tumor toxicity.
Conclusions:
- CAR-T therapy is a rapidly evolving field with significant potential for gastric cancer treatment.
- The selection of appropriate tumor-specific antigens is critical for the success of CAR-T immunotherapy.
- Continued research into novel biomarkers is essential for developing more effective and safer CAR-T therapies for GC.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...